La nave JUICE de la Agencia Espacial Europea (ESA) despegó a bordo de un Ariane 5 desde el Puerto Espacial Europeo de la Guayana Francesa a las 14:14 CEST del 14 de abril de 2023. El lanzamiento, realizado con éxito, marca el inicio de un ambicioso viaje para descubrir los secretos de …
Byondis B.V. announced that the Journal for ImmunoTherapy of Cancer has published encouraging preclinical data on its investigational monoclonal antibody BYON4228.
Benefits can be excellent incentives and tools for acquisition and retention — when they’re understood. Learn more about how to build better health benefits.
As more organizations adopt RPM, they’re facing increasingly complex challenges managing, updating and securing their devices.
Overcome the top 5 device management challenges of remote patient care with ease Read More »
Discover the transformative power of virtual rounding in healthcare, enabling real-time collaboration between practitioners and enhancing patient experience and outcomes.
The simple change hospitals are making to enhance patient care Read More »
Los objetos cósmicos exóticos conocidos como fuentes de rayos X ultraluminosas producen unos 10 millones de veces más energía que el Sol. De hecho, son tan brillantes que las observaciones indican que sobrepasan un límite físico llamado límite de Eddi …
¿Fuentes cósmicas de rayos X que incumplen las leyes de la física? Read More »
Se han detectado fugas de un líquido acuoso más caliente que el agua marina circundante y químicamente distinto de esta, brotando del fondo marino en una zona de subducción. Todo apunta a que se trata de una fuga del fluido que suaviza la fricción entre placas tect …
Medivir AB announces that a poster entitled ‘A triple combination of fostrox with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo,’ will be presented at the American Association for Cancer Research Annual Meeting by Fredrik Öberg, CSO at Medivir.
Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck Pharmaceuticals LLC announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. FDA met to discuss the supplemental New Drug Application of REXULTI® for the treatment of agitation associated with Alzheimer’s dementia.
Innovent Biologics, Inc. announced that the final analysis results of ORIENT-15, the Phase 3 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma were released in a poster presentation at the American Association for Cancer Research Annual Meeting 2023.
